Tech Center 1600 • Art Units: 1617 1623 1627
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760090 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 18134539 | METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS | Final Rejection | Vanderbilt University |
| 19198257 | FATTY ACID COMPOSITIONS | Final Rejection | Fera Diagnostics and Biologicals Corp. |
| 19177206 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Final Rejection | Teclison, Inc. |
| 17583526 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Final Rejection | The Johns Hopkins University |
| 19062916 | METHODS FOR TREATING ABERRANT BEHAVIOR AND MOTOR ACTIVITY | Non-Final OA | LAPKO INC, dba AFECTA PHARMACEUTICALS |
| 18285409 | COMPOSITION FOR INCREASING RED BLOOD CELLS AND/OR HEMOGLOBIN | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 16433298 | TREATMENT OF MIGRAINE | Final Rejection | Allergan Pharmaceuticals International Limited |
| 18845088 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | Non-Final OA | Mindstate Design Labs, Inc. |
| 18038821 | SIRTUIN 6 ACTIVATOR | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 17058046 | METHODS FOR TREATING SPINAL CORD INJURY | Final Rejection | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18567435 | FORMULATION CONTAINING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18581224 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE | Non-Final OA | Schedule 1 Therapeutics, Inc. |
| 17871152 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT | Final Rejection | UBE CORPORATION |
| 18549622 | BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS | Non-Final OA | Hanmi Pharm. Co., Ltd. |
| 18568899 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Non-Final OA | Scorpion Therapeutics, Inc. |
| 18006817 | Products for Treating the JNCL Disease | Non-Final OA | University College Cardiff Consultants Limited |
| 18287096 | FORMULATIONS OF CANNABINOIDS | Non-Final OA | ADD Advanced Drug Delivery Technologies LTD. |
| 16967824 | Treatment Of Patients With Classic Fabry Disease | Final Rejection | Amicus Therapeutics, Inc. |
| 18034245 | Lipid Prophylactic Brain Injury Treatment | Final Rejection | The United States of America as Represented by the Department of Veterans Affairs |
| 18275965 | Dosing Protocols for Administering Deuterated Arachidonic Acid or a Prodrug Thereof | Non-Final OA | BioJiva LLC |
| 17786175 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Non-Final OA | AGENEBIO, INC. |
| 18277746 | SALT AND CRYSTAL FORMS OF AN HMOX1 INDUCER | Non-Final OA | MITOBRIDGE INC. |
| 18273418 | PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS | Non-Final OA | HINYE PHARMACEUTICAL CO., LTD. |
| 18265525 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | Non-Final OA | Tonix Pharma Limited |
| 18268190 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | Final Rejection | Buck Institute for Research on Aging |
| 18256721 | MASITINIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Final Rejection | AB SCIENCE |
| 18328682 | ADJUNCTIVE THERAPY FOR DEPRESSION | Non-Final OA | ANeuroTech BV |
| 17790408 | COGNITIVE DISORDER PREVENTION AND THERAPY | Non-Final OA | ANeuroTech BV |
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | Non-Final OA | Crestone, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy